Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
4,612
datasets available to search
ShareScore release 0.9.0
Dataset results
4,612 results for “labelling”
DELETE (incorrect upload) - Dataset for Doshi et al. "The Possible Harms of Statins: What do Product Labels, Patient Package Inserts, and Pharmacy Leaflets Tell Us?"
<p>This dataset inadvertently contained the wrong files. The correct files are available at https://doi.org/10.5281/zenodo.1464310</p>
BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm
<p>The database is related to the article “BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm”. In this database we reported all the clinical and anamnestic data of the patients who completed the trial (e.g. 32 high-frequency episodic migraine subjects and 28 of them completed the trial). After a 28-day baseline period, subjects underwent 4 subsequent onabotulinum toxin-A treatments according to the phase III research evaluating migraine prophylaxis therapy (PREEMPT) paradigm, 12-weeks apart. Onabotulinum toxin-A reduced monthly migraine days by 3.68 days. Thirty-nine percent of the patients experienced a ≥50% reduction in monthly migraine days. Onabotulinum toxin-A also reduced the number of headache days and the intake of acute medications. Disability and quality of life (QoL) scores improved markedly.</p>
Is early MIDAS reduction at 3 months the best indicator predictor for erenumab treatment continuation? A open-label trial
<p>This database includes the raw data linked with the paper “Is early MIDAS reduction at 3 months the best indicator predictor for erenumab treatment continuation? A open-label trial”, published on The Journal of Headache and Pain.</p> <p> </p> <p>In this paper, we described migraine disability, quantified as a MIgraine Disability ASsessment (MIDAS).</p> <p>• A moderate to severe disability, MIDAS score 11, is required for prescription.</p> <p>• Score reduction of at least 50% after the first three months (T3) is mandatory to continue treatment.</p> <p>• Primary aim of this study:</p> <p>• - to evaluate whether 50% MIDAS reduction at T3 (MIDASRes) is a reliable response predictor of one-year erenumab treatment (classified as a reduction of baseline MMDs 50%).</p> <p>• The 50% reduction of monthly migraine days (MMD) at T3 Co-primary outcome</p> <p>• Secondary outcomes:</p> <p>• - the search of other predictors represents</p> <p> </p> <p>• Methods:</p> <p>• In this prospective, open-label study, 77 CM patients (mean age 49.8±9.5 years, chronicity history 13.1±10.3years, 93.5% of medication overuse headache) were treated with erenumab 70-140mg subcutaneous injections every 28 days for one year (T13). We assessed demographic and headache features, monthly migraine and headache days (MMD and MHDs respectively), days and doses of symptomatic intake. Patients also completed questionnaires evaluating migraine related disability (MIDAS and HIT-6), psychological comorbidities (HADS-A and HADS-D), quality of life (MSQ and 0 to 100 visual analogue scale) and allodynia (ASC-12). ANOVA for repeated measures was performed for quantifying erenumab efficacy and logistic regression model was used for evaluating one-year predictors of response.</p> <p> </p> <p>• Results:</p> <p>• Erenumab induced a sustained reduction of MMDs, MHDs and symptomatic intake during treatment. At T13 64.9% of patients presented MMDs baseline reduction 50% (RespondersT13). At T3, 55.8% of patients were MIDASRes. Contextually, 55.4% of patients were MMD Responders, these were also more likely to qualify as RespondersT13 when compared to non-responders (83.3% vs 42.9%; p=0.001). MMD response at T3 also demonstrated to be a predictor of long-term outcome according to a multivariate analysis ((Exp(B)=7.128; p=0.001)). When MIDAS reduction at T3 is considered as decision-making predictor of long-term outcome, 36.0% of patients who may benefit from 1-year erenumab administration are early excluded. By contrast, a lower percentage of Responders T13 (16%) would be discontinued if MIDASRes or MMD responders at T3 were alternatively considered.</p>
xMP: A Cross-lingual Multi-label Media Profiling Dataset
<p>We propose xMP, a zero-shot cross-linguistic assessment benchmark for factual and political bias in media coverage. We gathered data to create a multilingual test set of media profiling tasks in 34 languages and 18 language families. This allowed us to evaluate model performance and expand work based on English resources to other languages.</p>
Methylation pseudotime analysis for label-free profiling of the temporal chromatin landscape with long-read and single-molecule resolution [ATAC-seq]
GEO Series GSE290974. Homo sapiens. 16 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Chem-seq data from 5'-biotin-DRB-labelled human U2OS cells
GEO Series GSE106193. Homo sapiens. 2 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Bioluminescence-activated proximity labeling for spatial multi-omics
GEO Series GSE276085. Mus musculus; Homo sapiens. 27 samples. Type: Expression profiling by high throughput sequencing.
VL1/VL2 MARS LABELED RELEASE V1.0
The Labeled Release (LR) instrument on each Viking Lander operated throughout the Primary Mission and continued into the Extended Mission. The basic analysis cycle for the Labeled Release experiment was to deliver a sample of martian soil to one of four test cells, seal the cell and moisten the soil with an aqueous solution of carbon-14 labeled organic media. A second nutrient injection was typically done about 7-8 Mars days after the first injection. The test cell was continuously monitored for the release of radioactive labeled gas as an indicator of heterotrophic metabolism. Viking Lander 1 (VL1) conducted four analysis cycles with two nutrient injections for cycles 1, 2, and 4 and three injections for cycle 3. Viking Lander 2 (VL2) conducted five analysis cycles. The first four cycles had two nutrient injections each, and the fifth cycle had one injection [LEVIN&STRAAT1976B
The intracranial tumor segmentation challenge: ICTS 2021-image labels
<p>This dataset was retrieved from clinical work of radiosurgery. It contains brain tumor labels of 150 patients.</p>
20231127_Labelled metabolomes_Part2
Open the record for dataset details and reuse information.
labeled images
<p>labeled images</p>
satellite label data
<p>Label data</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.